Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

被引：0
|
作者：
Lu Si
Xiaoshi Zhang
Zhen Xu
Qiudi Jiang
Lilian Bu
Xuan Wang
Lili Mao
Weijiang Zhang
Nicole Richie
Jun Guo
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Sun Yat-sen University Cancer Center,undefined
[3] Roche Product Development in Asia Pacific,undefined
[4] Roche R&D Center China Ltd.,undefined
[5] Roche Innovation Center New York,undefined
[6] Genentech,undefined
[7] Inc.,undefined
来源：
BMC Cancer | / 18卷
关键词：
-positive; Advanced melanoma; Vemurafenib; China; Asia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
    Zhang, Weijiang
    McIntyre, Christine
    Kuhn, Melissa
    Forbes, Harper
    Kim, Tae Min
    Lee, Jeeyun
    Demidov, Lev
    Colburn, Dawn
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (08): : 1067 - 1073
  • [22] BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.
    Ribas, A.
    Kim, K. B.
    Schuchter, L. M.
    Gonzalez, R.
    Pavlick, A. C.
    Weber, J. S.
    McArthur, G. A.
    Hutson, T. E.
    Flaherty, K. T.
    Moschos, S. J.
    Lawrence, D. P.
    Hersey, P.
    Kefford, R. F.
    Chmielowski, B.
    Puzanov, I.
    Li, J.
    Nolop, K. B.
    Lee, R. J.
    Joe, A. K.
    Sosman, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)
    Paolo A Ascierto
    Grant A. McArthur
    Brigitte Dréno
    James Larkin
    Gabriella Liszkay
    Michele Maio
    Mario Mandala
    Lev Demidov
    Daniil Stroyakovskiy
    Luc Thomas
    Luis de la Cruz-Merino
    Victoria Atkinson
    Caroline Dutriaux
    Claus Garbe
    Ilsung Chang
    Stephen P. Hack
    Antoni Ribas
    Journal of Translational Medicine, 13 (Suppl 1)
  • [24] Open-label, multicenter, single-arm, phase I, dose-dscalation with efficacy tail extension study of vemurafenib in pediatric patients with surgically incurable and unresectable stage IIIc or IV melanoma harboring BRAFV600 mutations (NCT01519323).
    Navid, Fariba
    Chishoim, Julia C.
    Ferrari, Andrea
    Herzog, Cynthia E.
    Rodriguez-Galindo, Carlos
    Hauschild, Axel
    Krishnan, Kartik
    Pappo, Alberto S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma
    Dreno, Brigitte
    Ascierto, Paolo A.
    Atkinson, Victoria
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Bartley, Karen
    Karagiannis, Thomas
    Chang, Ilsung
    Rooney, Isabelle
    Koralek, Daniel O.
    Larkin, James
    McArthur, Grant A.
    Ribas, Antoni
    BRITISH JOURNAL OF CANCER, 2018, 118 (06) : 777 - 784
  • [26] AN OPEN-LABEL, MULTICENTRE SAFETY STUDY OF VEMURAFENIB IN PATIENTS WITH METASTATIC MELANOMA
    Blank, C.
    Del Vecchio, M.
    Ascierto, P. A.
    Queirolo, P.
    Hauschild, A.
    Arance, A.
    Brown, M.
    Mitchell, L.
    Veronese, L.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 366 - 366
  • [27] Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study
    Del Vecchio, Michele
    Ascierto, Paolo Antonio
    Mandala, Mario
    Sileni, Vanna Chiarion
    Maio, Michele
    Di Guardo, Lorenza
    Simeone, Ester
    Queirolo, Paola
    FUTURE ONCOLOGY, 2015, 11 (09) : 1355 - 1362
  • [28] Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib
    Lewis, Karl
    Hauschild, Axel
    Larkin, James
    Ribas, Antoni
    Flaherty, Keith T.
    McArthur, Grant A.
    Dreno, Brigitte
    McKenna, Edward
    Zhu, Qian
    Mun, Yong
    Ascierto, Paolo A.
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 45 - 55
  • [29] Safety and Efficacy of Vemurafenib in Patients with BRAFV600 Mutation-Positive Metastatic Melanoma Previously Treated with Ipilimumab: a Subgroup Analysis from a Vemurafenib Expanded Access Program
    Hamid, O.
    Flaherty, L.
    Day, B. -M
    Abhyankar, S.
    Hainsworth, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 54 - 55
  • [30] FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
    Kim, Geoffrey
    Mckee, Amy E.
    Ning, Yang-Min
    Hazarika, Maitreyee
    Theoret, Marc
    Johnson, John R.
    Xu, Qiang Casey
    Tang, Shenghui
    Sridhara, Rajeshwari
    Jiang, Xiaoping
    He, Kun
    Roscoe, Donna
    McGuinn, W. David
    Helms, Whitney S.
    Russell, Anne Marie
    Miksinski, Sarah Pope
    Zirkelbach, Jeanne Fourie
    Earp, Justin
    Liu, Qi
    Ibrahim, Amna
    Justice, Robert
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (19) : 4994 - 5000
12345